NYSE:HIMS Hims & Hers Health (HIMS) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free HIMS Stock Alerts $11.74 -0.61 (-4.94%) (As of 02:03 PM ET) Add Compare Share Share Today's Range$11.64▼$12.0850-Day Range$11.25▼$16.7252-Week Range$5.65▼$17.16Volume7.61 million shsAverage Volume5.10 million shsMarket Capitalization$2.52 billionP/E RatioN/ADividend YieldN/APrice Target$15.07 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Hims & Hers Health alerts: Email Address Hims & Hers Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside28.6% Upside$15.07 Price TargetShort InterestBearish12.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 54 Articles This WeekInsider TradingSelling Shares$9.73 M Sold Last QuarterProj. Earnings Growth127.27%From $0.11 to $0.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.99 out of 5 starsMedical Sector175th out of 903 stocksOffices & Clinics Of Medical Doctors Industry1st out of 7 stocks 4.3 Analyst's Opinion Consensus RatingHims & Hers Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 9 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageHims & Hers Health has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Hims & Hers Health's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.52% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 34.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HIMS. Previous Next 1.9 News and Social Media Coverage News SentimentHims & Hers Health has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 54 news articles for Hims & Hers Health this week, compared to 7 articles on an average week.Search InterestOnly 33 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.MarketBeat FollowsOnly 26 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -19% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,733,700.00 in company stock.Percentage Held by Insiders31.63% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hims & Hers Health's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Hims & Hers Health are expected to grow by 127.27% in the coming year, from $0.11 to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is -106.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is -106.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 7.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Hims & Hers Health's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCould this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.Access my full "Cut & Paste" profit analysis now. About Hims & Hers Health Stock (NYSE:HIMS)Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.Read More HIMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIMS Stock News HeadlinesMay 7, 2024 | marketbeat.comHims & Hers Health Stock Could Become a Wealth CompounderShares of Hims & Hers Health Inc. NYSE: HIMS are jumping by as much as 15.5% after the company released its first quarter 2024 earnings results. This quarter is arguably the most important quarter as it sets the tone for the rest of the year in any stock.May 7, 2024 | marketbeat.comHims & Hers Health Stock Could Become a Wealth Compounder (HIMS)Hims & Hers stock could give investors the best of both stability and double-digit upside through EPS projections and price targets, especially after 1Q24May 8, 2024 | Behind the Markets (Ad)Could this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.May 4, 2024 | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird Sells 11,750 SharesMay 2, 2024 | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $31,437.68 in StockApril 9, 2024 | insidertrades.comMelissa Baird Sells 11,751 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockApril 9, 2024 | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 188,888 SharesMay 8, 2024 | markets.businessinsider.comHims & Hers Health's Model 'Proving Effective': 2 Analysts Examine Q1 EarningsMay 8, 2024 | Behind the Markets (Ad)Could this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.May 8, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Price Target Raised to $13.00 at Piper SandlerMay 8, 2024 | seekingalpha.comHims & Hers: The Growth Story, Coupled With Expanding Profitability, Promises Exponential GainsMay 8, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Sees Strong Trading Volume Following Better-Than-Expected EarningsMay 8, 2024 | americanbankingnews.comStock Traders Buy High Volume of Hims & Hers Health Call Options (NYSE:HIMS)May 7, 2024 | msn.comHims & Hers Health, Inc. (NYSE:HIMS) Q1 2024 Earnings Call TranscriptMay 7, 2024 | msn.comThese Stocks Are Moving the Most Today: Palantir, Disney, Peloton, Lucid, BP, UBS, Hims & Hers Health, Datadog, Beyond, and MoreMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Hims & Hers Health Amidst Strong Quarterly Performance and Positive OutlookMay 7, 2024 | fool.comWhy Hims & Hers Health Stock Popped 17.1% TodayMay 7, 2024 | fool.comWhy Hims & Hers Health Stock Popped 17.1% TodayMay 7, 2024 | seekingalpha.comHims & Hers Health: Still Firing On Strong CylindersMay 6, 2024 | uk.finance.yahoo.comHims & Hers Health Inc (HIMS) Surpasses Q1 Revenue and Earnings Estimates with Strong ...May 6, 2024 | marketwatch.comHims & Hers Health Shares Climb 11%, Expects To Hit 2025 Targets This YearMay 6, 2024 | msn.comHIMS Stock Earnings: Hims & Hers Health Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | msn.comHims & Hers shares rally as forecast bumped higher and more profitability said to be aheadMay 6, 2024 | finance.yahoo.comHim & Hers Health stock soars on Q1 revenue beat, Q2 guidanceMay 6, 2024 | msn.comHims & Hers Health CEO Under Fire After Expressing Support For Pro-Palestinian Student Protesters, Company Stock PlummetsMay 6, 2024 | msn.comGo woke, go broke: Hims & Hers boss Andrew Dudum is a morally bankrupt Dud by name — and by natureMay 6, 2024 | marketwatch.comHims & Hers Health Lifts FY Revenue Outlook on 1Q Revenue, Subscription GrowthSee More Headlines Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/08/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryN/A Current SymbolNYSE:HIMS CUSIPN/A CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees1,046Year FoundedN/APrice Target and Rating Average Stock Price Target$15.07 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+27.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E Ratio107.09 P/E GrowthN/ANet Income$-23,550,000.00 Net Margins-2.70% Pretax Margin-2.47% Return on Equity-7.21% Return on Assets-5.81% Debt Debt-to-Equity RatioN/A Current Ratio3.00 Quick Ratio2.74 Sales & Book Value Annual Sales$872 million Price / Sales2.89 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book7.32Miscellaneous Outstanding Shares214,250,000Free Float146,483,000Market Cap$2.52 billion OptionableOptionable Beta0.97 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Andrew Dudum (Age 35)Co-Founder, Chairman & CEO Comp: $1.7MMr. Yemi Okupe (Age 38)Chief Financial Officer Comp: $804.05kMs. Melissa Baird (Age 46)Chief Operating Officer Comp: $917.67kMs. Irene A. Becklund (Age 39)Senior VP, Controller & Principal Accounting Officer Comp: $361.12kMs. Soleil Teubner Boughton (Age 45)Chief Legal Officer & Corporate Secretary Comp: $782.66kMr. Mike Chi (Age 43)Chief Marketing Officer Comp: $514.77kDr. Patrick Carroll M.D. (Age 66)Chief Medical Officer, Member of Medical Advisory Board & Director Comp: $27.03kMs. Khobi BrooklynChief Communications OfficerMs. Amee ParekhSenior Vice President of Human ResourcesDr. Peter Stahl M.D.Senior VP & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsTeladoc HealthNYSE:TDOCTG TherapeuticsNASDAQ:TGTXLifeStance Health GroupNASDAQ:LFSTNeogenNASDAQ:NEOGMorphoSysNASDAQ:MORView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Sold 41,992 shares on 5/8/2024Ownership: 0.058%Headlands Technologies LLCBought 14,765 shares on 5/8/2024Ownership: 0.007%Swiss National BankBought 2,000 shares on 5/7/2024Ownership: 0.131%Sei Investments Co.Bought 37,890 shares on 5/7/2024Ownership: 0.026%IvyRock Asset Management HK LtdBought 28,000 shares on 5/7/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions HIMS Stock Analysis - Frequently Asked Questions Should I buy or sell Hims & Hers Health stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares. View HIMS analyst ratings or view top-rated stocks. What is Hims & Hers Health's stock price target for 2024? 15 brokers have issued 1-year price objectives for Hims & Hers Health's shares. Their HIMS share price targets range from $10.00 to $20.00. On average, they predict the company's stock price to reach $15.07 in the next year. This suggests a possible upside of 28.6% from the stock's current price. View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts. How have HIMS shares performed in 2024? Hims & Hers Health's stock was trading at $8.90 on January 1st, 2024. Since then, HIMS stock has increased by 31.7% and is now trading at $11.72. View the best growth stocks for 2024 here. Are investors shorting Hims & Hers Health? Hims & Hers Health saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 17,470,000 shares, an increase of 34.6% from the March 31st total of 12,980,000 shares. Based on an average daily volume of 5,020,000 shares, the days-to-cover ratio is currently 3.5 days. Currently, 12.5% of the company's shares are sold short. View Hims & Hers Health's Short Interest. When is Hims & Hers Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our HIMS earnings forecast. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) released its earnings results on Monday, May, 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative trailing twelve-month return on equity of 7.21% and a negative net margin of 2.70%. The firm's revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.05) EPS. What ETFs hold Hims & Hers Health's stock? ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include Amplify Online Retail ETF (IBUY), Global X Telemedicine & Digital Health ETF (EDOC), SPDR S&P Health Care Services ETF (XHS), Fidelity Digital Health ETF (FDHT), iShares Virtual Work and Life Multisector ETF (IWFH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Hims & Hers Health issued on next quarter's earnings? Hims & Hers Health updated its second quarter 2024 earnings guidance on Monday, May, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $292.0 million-$297.0 million, compared to the consensus revenue estimate of $288.1 million. Who are Hims & Hers Health's major shareholders? Hims & Hers Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mckinley Capital Management LLC (0.30%), Mirae Asset Global Investments Co. Ltd. (0.13%), Swiss National Bank (0.13%), Summit Trail Advisors LLC (0.13%), Quantbot Technologies LP (0.10%) and GSA Capital Partners LLP (0.10%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:HIMS) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
